EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Integrative cell subtype-to-drug discovery technology for angiomyolipomas ​treatment

Junxian Cao, Xiao Chang, Shiwen Deng, Hongjun Yang, Gang Guo, Peng Chen

Biomedical Technology · 2025-12 · 12 · 100117

DOI: 10.1016/j.bmt.2025.100117 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomedical Technology, 2025-12. Verfasst von Junxian Cao und 5 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Beijing Nova Program, National Natural Science Foundation of China.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tuberous sclerosis complex mutation renal angiomyolipomas (TSC-RAML) are benign tumors driven by abnormal growth of mesenchymal-derived cells. Although mTOR inhibitors are clinically used, drug resistance and incomplete tumour shrinkage highlight the need for new treatment approaches. Here, we developed a new strategy combining single-cell transcriptomics, network pharmacology, and functional experiments to identify targeted therapies for TSC-RAMLs. Single-cell RNA sequencing of tumour tissues from 4 TSC-RAML patients uncovered a distinct mesenchymal subpopulation (TSC-RAML-Cells) with upregulated pathways in adipogenesis and mTOR signalling. Using high-dimensional weighted gene co-expression network analysis (hdWGCNA) on TSC-RAML-Cells, we identified three disease-associated modules containing hub genes critical for tumour survival. Cross-referencing these modules with the Connectivity Map (CMAP) drug database prioritized AS-605240 as a potential therapeutic candidate. Protein-protein interaction (PPI) network analysis further revealed PI3KCA as a central target, and molecular dynamics simulations confirmed stable binding between AS-605240 and PI3KCA, with a binding free energy of −7.8 ​kcal/mol, supporting its mechanism of action. In vitro experiments using patient-derived TSC-RAML cells showed that AS-605240 suppressed cell growth in a dose-dependent manner (IC50 ​= ​7.8 ​μM) and increased apoptosis rates through inhibition of the PI3K/AKT pathway. This work not only proposes AS-605240 as a promising therapy for TSC-RAMLs but also provides a scalable “cell subtype-to-drug" discovery framework. By integrating single-cell omics and computational drug repurposing, this approach accelerates precision medicine development for rare diseases.

Förderung

  • Beijing Nova Program
  • National Natural Science Foundation of China

Zitieren

APA

Cao, J., Chang, X., Deng, S., Yang, H., Guo, G., & Chen, P. (2025). Integrative cell subtype-to-drug discovery technology for angiomyolipomas ​treatment. Biomedical Technology, 12, 100117. https://doi.org/10.1016/j.bmt.2025.100117

Vancouver

Cao J, Chang X, Deng S, Yang H, Guo G, Chen P. Integrative cell subtype-to-drug discovery technology for angiomyolipomas ​treatment. Biomedical Technology. 2025;12:100117. doi:10.1016/j.bmt.2025.100117

BibTeX
@article{Cao2025,
  author = {Cao, Junxian and Chang, Xiao and Deng, Shiwen and Yang, Hongjun and Guo, Gang and Chen, Peng},
  title = {Integrative cell subtype-to-drug discovery technology for angiomyolipomas ​treatment},
  journal = {Biomedical Technology},
  year = {2025},
  volume = {12},
  pages = {100117},
  doi = {10.1016/j.bmt.2025.100117}
}
Kostenlos starten →